Who
Yanina Grant-Huerta
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, ImageneBio; Chief Accounting Officer, Atara Biotherapeutics.
In numbers
- Trades disclosed
- 25
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $125K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 16 May 2025
- Last trade
- 14 Aug 2026
- Last filed
- 17 Aug 2026
Companies traded
Activity over time
1 May 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Aug 2026filed 17 Aug 2026 | IMA ImageneBioBiotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 14 Aug 2026filed 17 Aug 2026 | IMA ImageneBioBiotechnology | SEC FORM 4 Code A | —39,000 at $0.00 | filing |
| 14 Aug 2026filed 17 Aug 2026 | IMA ImageneBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —56,000 at $0.00 | filing |
| 14 Aug 2026filed 17 Aug 2026 | IMA ImageneBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —56,000 at $0.00 | filing |
| 14 Aug 2026filed 17 Aug 2026 | IMA ImageneBioBiotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 14 Aug 2026filed 17 Aug 2026 | IMA ImageneBioBiotechnology | SEC FORM 4 Code A | —39,000 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $22K2,414 at $9.13 | filing |
| 18 May 2026filed 20 May 2026 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $22K2,414 at $9.13 | filing |
| 9 Mar 2026filed 11 Mar 2026 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —20,300 at $0.00 | filing |
| 9 Mar 2026filed 11 Mar 2026 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —20,300 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $12224 at $5.08 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $8,1451,603 at $5.08 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $1,916377 at $5.08 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $508100 at $5.08 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $12224 at $5.08 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $8,1431,603 at $5.08 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $1,915377 at $5.08 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $508100 at $5.08 | filing |
| 17 Nov 2025filed 19 Nov 2025 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $22K1,645 at $13.19 | filing |
| 17 Nov 2025filed 19 Nov 2025 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $1,12185 at $13.19 | filing |
News
No headline names them, or the companies they trade most, lately.